AzTrials
AzTrials

GastroparesisGESNCT02159586

Cardiac Vagal Effects of GES in Patients With Gastroparesis and Vagal Nerve Action Potentials in Vagus Nerve

An observational study of Gastroparesis, run by Indiana University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of this study is to determine if Gastric Electrical Stimulation may influence vagal outflow via vagal afferent fibers that terminate in the Central Nervous System. Read more about this study

Who is it for?
Ages 18 to 90 years
Conditions the study is for
Gastroparesis
What is being tested?
gastric electrical stimulator
Type of treatment
Medical device
How many people
158 participants
Where
1 siteUnited States
Study dates
1 Nov 2012to 16 Sep 2024
How long will I take part?
2 Years
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: This study will evaluate male and female patients at least 18 years of age, with gastroparesis, who will or have already undergone the implantation of a GES device (Enterra, Medtronic, Minneapolis, MN)

Who may be able to join

  • At least 18 years of age.
  • Documented diagnosis of gastroparesis.
  • Will undergo implantation of a GES device or already has a GES device implanted

Who cannot join

  • Pregnancy
  • History of allergic reaction to EKG lead placement adhesives.
  • unable to give informed consent

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Indiana University Hospital

    Indianapolis, Indiana, 46202

Other trials in United States

About this study

Official title: Cardiac Vagal Effects of Gastric Electrical Stimulation and Vagal Nerve Action Potentials in Vagus Nerve in Patients With Gastroparesis

The objective of this study is to determine if Gastric Electrical Stimulation may influence vagal outflow via vagal afferent fibers that terminate in the Central Nervous System.

Read the detailed description

All patients who are going to have a GES device implanted, or who already have the device are eligible to be part of the study. They will be followed according to the time point they enter the study and its schedule. The visit procedures will be conducted at the discretion of the investigator dependent on the clinical condition of the subject at that time. The study involves EKG and vagal nerve recordings. Three EKG electrodes will be placed (one on chest and 2 on either arms or legs). Separate electrodes will be placed on the neck overlying the vagus nerves

Baseline (Pre-GES Implantation) Visit:

Subjects who are being seen in clinic for possible gastroparesis and may be a possible candidate for GES later or will be undergoing the GES implantation may have a baseline visit. . The baseline visit can be held either at the time of the clinic visit or before the GES implantation. If the baseline visit occurs on the day of the GES implantation, 2 separate EKGs will be performed, one prior to GES pacemaker device implantation for up to a duration of 5 minutes and the second one after the implantation in the recovery room. This EKG will be performed for a total duration of up to 15 minutes with 5 minute "ON", 5 minutes :OFF" and another 5 minutes in the "ON" position. At the same visit with each EKG recording separate EKG electrode will be placed on the neck overlying the vagus nerve. Vagal nerve recordings will be documented for a total duration of upto 15 minutes with approximately 5 min at "ON", 5 min "OFF" and another 5 min "ON" settings of the stimulator in conjunction with the EKG recordings.

At the baseline visit separate EKG electrodes will also be placed on the neck overlying the vagus nerve and a 5 minute recording will be made in conjunction with the EKG recordings.\ before the implantation.

If the subjects already have the GES device implanted then a baseline visit will not be required. They will be included in the study at the time the consent form is signed and will be followed as needed according to the clinic visit schedule and at the discretion and clinical judgement of the investigator.

Post-GES Implantation Visits:

The subject may be asked at the clinic visits to repeat the EKG and vagal nerve study procedures at the discretion and clinical judgment of the investigator.

EKG electrodes will be placed on the chest and arms/legs, and vagal nerve electrodes will be placed on the neck overlying the vagus nerve. A butterfly catheter is inserted under aseptic conditions into a peripheral vein. Fifteen ml (1 tablespoon) of blood is withdrawn and placed on ice (labeled Baseline). With the subject at rest recordings may be made for upto a total duration of 15- 20 minutes. After 15- 20 minutes of recordings the GES device is then turned "OFF" and recordings will be made for up to 40 minutes. After 40 minutes additional 15 ml (1 tablespoon) of blood is withdrawn after the device has been in the OFF position for 40 minutes (labeled "OFF"). The device is then turned back in the "ON" position with the GES settings either at the original or changed settings from the previous settings based on the clinical judgement of the investigators, The EKG and vagal recordings may be made for up to 15-20 minutes. After 15- 20 minutes in the ON position 15 ml (1 tablespoon) is then withdrawn (labeled "ON". The butterfly catheter is then withdrawn, and a bandage is placed at the venipuncture site. The final setting on the GES will depend on the clinical decision of the investigator based on the subject's symptoms and presentation to the clinic.

Conditions
Gastroparesis
Being tested
gastric electrical stimulator
Keywords
gastroparesis, gastric electrical stimulator, GES, vomiting, nausea, bloating, postprandial fullness, epigastric pain
Medical subject headings
Gastroparesis, Vomiting, Nausea

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • gastric electrical stimulatorDevice

Study groups in NCT02159586
Study groupRoleWhat they receive
GES subjectsmale and female patients at least 18 years of age, with gastroparesis, who will or have already undergone the implantation of a GES device
Receives: Device: gastric electrical stimulator

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Determine if GES influences vagal outflow

    To determine if GES may influence vagal outflow via vagal afferent fibers that terminate in the Central Nervous System; EKG electrodes will be placed on the chest, stomach, jugular, and vagas nerves. The purpose of this is to record the effects of the stimulator when on and off. The ECG signals are digitized with an ECG power amplifier, Power Lab by AD Instruments. The digitized signals are analyzed with an ECG software analysis system, Lab Chart. The analysis will look for heart rate variability, total power variability, and frequency variability. This will determine if stimulation has an effect on these levels.

    Measured: 2-3 years

Secondary outcomes (2)
  1. Release of hormones

    The purpose of this investigation is to determine whether gastric electrical stimulation of the stomach via a surgically implanted stimulation device is associated with gastrointestinal hormone release in human subjects. Blood draws will be obtained in tandem with each of the 3 phases of EKG recordings. The blood samples will be processed and serum will be sent to an IU Lab for Hormone analysis to see if typical hormone levels associated with digestion increase or decrease with the addition/subtraction of the gastric stimulation.

    Measured: 2-3 years

  2. Vagus nerve anatomy

    To optimize the methods for determining electrode placement around the cervical vagus nerve. The development of a method to record and analyze compound action potentials from the vagus nerve will enhance our knowledge of the mechanism of action of VNS in the treatment of gastroparesis.

    Measured: 2-3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jun 2014 (estimated)
  2. Study start1 Nov 2012
  3. Primary completion16 Sep 2024
  4. Study completion16 Sep 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
158 participants (actual)
Target duration
2 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT02159586
Sponsor's protocol ID
EKG/Vagal Nerve
Other IDs
1206008988
Acronym
GES
Status last verified
Aug 2026
First submitted
6 Jun 2014
Last updated
1 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Gastroparesis, run by Indiana University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Determine if GES influences vagal outflow (time frame: 2-3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in